市場調査レポート

商品コード

1458092

糖尿病性網膜症の世界市場規模、シェア、成長分析、タイプ別、管理別-産業予測、2024～2031年

Global Diabetic Retinopathy Market Size, Share, Growth Analysis, By Type(Proliferative Diabetic Retinopathy, and Non-proliferative diabetic retinopathy), By Management(Anti-VEGF, Intraocular Steroid Injection) - Industry Forecast 2024-2031

出版日: 2024年03月23日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 830,828円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 971,912円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,112,996円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

糖尿病性網膜症の世界市場規模は2022年に83億米ドルと評価され、2023年の88億3,000万米ドルから2031年には145億1,000万米ドルに拡大し、予測期間（2024～2031年）のCAGRは6.4％で成長する展望です。

市場の拡大は、糖尿病の罹患率の増加、高齢化人口の増加、糖尿病に関連する失明の増加など、いくつかの要因によって推進されると予想されます。さらに、糖尿病に対する意識の高まりや新製品の採用も市場拡大に寄与しています。糖尿病は、膵臓からのインスリン分泌不全を特徴とする世界の疾患であり、血糖値の上昇と網膜の毛細血管へのダメージをもたらし、糖尿病性網膜症を引き起こします。高い血糖値と不十分なモニタリングは網膜変性の危険因子と考えられているが、糖尿病の早期発見、適切な投薬、最新のツールを使用した継続的な自己モニタリング、健康的なライフスタイルを取り入れることで、網膜の損傷を軽減し、糖尿病性網膜症の発生率を低下させることができます。予防努力にもかかわらず、糖尿病性網膜症は不可逆的な失明につながる可能性があるため、AIを活用して糖尿病性網膜症のスクリーニングを行うヘルステック企業、Check Eyeが提供するような早期発見戦略が必要となります。英国では、糖尿病性網膜症が失明の主要原因のひとつにランクされており、消費者の意識向上と医療支出の増加が重要であることが浮き彫りになっています。さらに、世界の高齢化率は2050年までに3倍になると予測されており、糖尿病とその合併症に伴うリスクを軽減するためには、健康的なライフスタイルの維持と定期的な血糖値のモニタリングが不可欠です。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

糖尿病性網膜症の世界市場：タイプ別

市場概要
増殖性糖尿病性網膜症
非増殖性糖尿病性網膜症

糖尿病性網膜症の世界市場：管理別

市場概要
抗VEGF
ステロイド眼内注射
レーザー手術
硝子体切除術

糖尿病性網膜症の世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

Novartis AG
Roche Holding AG
Bayer AG
Regeneron Pharmaceuticals, Inc.
Allergan plc（AbbVie Inc.）
Carl Zeiss Meditec AG
Topcon Corporation
Nidek Co., Ltd.
Optos plc（Nikon Corporation）
Bausch Health Companies Inc.
Alcon Inc.
Santen Pharmaceutical Co., Ltd.
Lumenis Ltd.（XIO Group）
Iridex Corporation
Leica Microsystems（Danaher Corporation）
StemCells Inc.（Microbot Medical Inc.）
Bioptigen, Inc.（Metabolic Technologies Inc.）
CenterVue SpA
Visunex Medical Systems, Inc.
Clarity Medical Systems, Inc.

Product Code: SQMIG35A2516

Global Diabetic Retinopathy Market size was valued at USD 8.30 billion in 2022 and is poised to grow from USD 8.83 billion in 2023 to USD 14.51 billion by 2031, growing at a CAGR of 6.4% during the forecast period (2024-2031).

The market expansion is expected to be propelled by several factors including the increasing incidence of diabetes, a growing aging population, and the rise in diabetes-related blindness. Additionally, heightened awareness of diabetes and the introduction of new products are contributing to market growth. Diabetes, a prevalent global condition characterized by the pancreas' inability to produce insulin, leads to elevated blood sugar levels and damage to retinal blood capillaries, resulting in diabetic retinopathy. High blood sugar levels and inadequate monitoring are considered risk factors for retinal degeneration, but early detection of diabetes, proper medication, continuous self-monitoring using modern tools, and embracing a healthy lifestyle can mitigate retinal damage and lower the incidence of diabetic retinopathy. Despite preventive efforts, diabetic retinopathy can lead to irreversible blindness, necessitating early detection strategies like those offered by Check Eye, a healthtech company leveraging AI to screen for diabetic retinopathy. In the UK, diabetic retinopathy ranks among the leading causes of blindness, underscoring the importance of consumer awareness and increased healthcare spending. Moreover, with the global aging population projected to triple by 2050, maintaining a healthy lifestyle and regular blood glucose monitoring are imperative to mitigate the risks associated with diabetes and its complications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Retinopathy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Retinopathy Market Segmental Analysis

The global diabetic retinopathy market is segmented based on type, management, and region. Based on type, the market is segmented into proliferative diabetic retinopathy, and non-proliferative diabetic retinopathy. With respect to categorization by management, the market is segmented into anti-VEGF, intraocular steroid injection, laser surgery, vitrectomy. Regionwise, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Diabetic Retinopathy Market

The diabetic retinopathy market is witnessing significant expansion, propelled by augmented investments in healthcare infrastructure, which foster improved healthcare provision and accessibility. Concurrently, concerted endeavors by public and private entities to boost awareness regarding diabetic retinopathy are bolstering market growth. Furthermore, favorable reimbursement conditions and a populace with substantial disposable income are fostering the market's expansion. The demographic shift towards an aging population, coupled with evolving lifestyles, further accelerates the market's growth trajectory.

Restraints in the Global Diabetic Retinopathy Market

The increasing occurrence of diabetic retinopathy is accompanied by insufficient awareness regarding the condition and the necessity of regular eye check-ups among individuals with diabetes. Restricted availability of eye care services, especially in remote or underserved regions, poses obstacles to early detection and prompt intervention.

Market Trends of the Global Diabetic Retinopathy Market

Increasingly acknowledged is the pivotal role of early detection and intervention in addressing diabetic retinopathy, with emphasis shifting towards implementing routine screening initiatives, raising awareness through campaigns, and adopting cutting-edge imaging techniques to facilitate prompt diagnosis, thereby enabling timely therapeutic interventions and more effective disease management.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Diabetic Retinopathy Market by Type

Market Overview
Proliferative Diabetic Retinopathy
and Non-proliferative diabetic retinopathy

Global Diabetic Retinopathy Market by Management

Market Overview
Anti-VEGF
Intraocular Steroid Injection
Laser Surgery
and Vitrectomy

Global Diabetic Retinopathy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan plc (AbbVie Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carl Zeiss Meditec AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Topcon Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nidek Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Optos plc (Nikon Corporation)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lumenis Ltd. (XIO Group)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Iridex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Leica Microsystems (Danaher Corporation)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
StemCells Inc. (Microbot Medical Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioptigen, Inc. (Metabolic Technologies Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CenterVue SpA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Visunex Medical Systems, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clarity Medical Systems, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments